Alector to Participate in the Stifel Healthcare Conference
08 Novembro 2023 - 9:00AM
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology
company pioneering immuno-neurology, today announced management
will participate in a fireside chat at the Stifel Healthcare
Conference on Tuesday, November 14, 2023, at 11:30 a.m.
ET.
A live webcast of the fireside chat will be
available on the “Events & Presentations” page within the
Investors section of the Alector website
at http://investors.alector.com. A replay will be available on
the Alector website for 90 days following the event.
About Alector Alector is a clinical-stage
biotechnology company pioneering immuno-neurology, a novel
therapeutic approach for the treatment of neurodegenerative
diseases. Immuno-neurology targets immune dysfunction as a root
cause of multiple pathologies that are drivers of degenerative
brain disorders. Alector has discovered and is developing a broad
portfolio of innate immune system programs, designed to
functionally repair genetic mutations that cause dysfunction of the
brain’s immune system and enable rejuvenated immune cells to
counteract emerging brain pathologies. Alector’s immuno-neurology
product candidates are supported by biomarkers and seek to treat
indications, including Alzheimer’s disease and genetically defined
frontotemporal dementia patient populations. Alector is
headquartered in South San Francisco, California. For additional
information, please visit www.alector.com.
Alector Contacts:
AlectorKatie Hogan202-549-0557katie.hogan@alector.com
1AB (media)Dan Budwick973-271-6085 dan@1abmedia.com
Argot Partners (investors)Laura
Perry212.600.1902alector@argotpartners.com
Alector (NASDAQ:ALEC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Alector (NASDAQ:ALEC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024